tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Roden, 12 are a BUY (92.31%), 1 are a HOLD (7.69%).
Analyst Matthew Roden works with a stock forecast success ratio of 95.48% fulfilled within 393 days on average. Previously, Matthew Roden worked at UBS.
Matthew Roden’s has documented 98 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on GILD, Gilead Sciences at 29-Apr-2016.
Analyst best performing recommendations are on CELG (CELGENE).
The best stock recommendation documented was for CELG (CELGENE) at 6/30/2015. The price target of $130 was fulfilled within 15 days with a profit of $14.27 (12.33%) receiving and performance score of 8.22.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
101
$-7.24 (-6.69%)
101
4 years 5 months 25 days ago
2/8 (25%)
$-7.53 (-6.94%)
171
Hold
115
$6.76 (6.25%)
102
4 years 5 months 25 days ago
3/12 (25%)
$6.47 (5.96%)
382
Hold
100
$-8.24 (-7.61%)
128
4 years 8 months 7 days ago
3/6 (50%)
$4.78 (5.02%)
159
Buy
102
$-6.24 (-5.76%)
105
4 years 11 months 23 days ago
3/3 (100%)
$5.12 (5.28%)
270
Hold
100
$-8.24 (-7.61%)
100
5 years 21 days ago
2/7 (28.57%)
$5.2 (5.49%)
282
What Year was the first public recommendation made by Matthew Roden?
